Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Dec 14;60(3):1865-8.
doi: 10.1128/AAC.01609-15.

Novel Bone-Targeting Agent for Enhanced Delivery of Vancomycin to Bone

Zaineb A F Albayati  1 , Manjula Sunkara  2 , Suzannah M Schmidt-Malan  3 , Melissa J Karau  3 , Andrew J Morris  2 , James M Steckelberg  4 , Robin Patel  5 , Philip J Breen  1 , Mark S Smeltzer  6 , K Grant Taylor  7 , Kevyn E Merten  8 , William M Pierce  9 , Peter A Crooks  10
Affiliations

Novel Bone-Targeting Agent for Enhanced Delivery of Vancomycin to Bone

Zaineb A F Albayati et al. Antimicrob Agents Chemother. .

Abstract

We examined the pharmacokinetic properties of vancomycin conjugated to a bone-targeting agent (BT) with high affinity for hydroxyapatite after systemic intravenous administration. The results confirm enhanced persistence of BT-vancomycin in plasma and enhanced accumulation in bone relative to vancomycin. This suggests that BT-vancomycin may be a potential carrier for the systemic targeted delivery of vancomycin in the treatment of bone infections, potentially reducing the reliance on surgical debridement to achieve the desired therapeutic outcome.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Structures of vancomycin (left) and BT-vancomycin (right).
FIG 2
FIG 2
Plasma concentration-time profile of vancomycin (circles) and BT-vancomycin (squares) after i.v. administration of 50 mg/kg vancomycin or 63.85 mg/kg BT-vancomycin (molar equivalent to 50 mg/kg vancomycin). Results are the mean ± SEM (n = 5 rats). *, significantly higher than results for vancomycin, P < 0.05; **, significantly higher than results for vancomycin, P < 0.01; ***, significantly higher than results for vancomycin, P < 0.0001.
FIG 3
FIG 3
Concentration-time profile in bone of vancomycin (circles) and BT-vancomycin (squares) after i.v. administration of vancomycin (50 mg/kg) or BT-vancomycin (63.85 mg/kg). Results are the mean ± SEM (n = 5 rats per group). *, significantly higher than results for vancomycin, P < 0.05; **, significantly higher than results for vancomycin, P < 0.01; ***, significantly higher than results for vancomycin, P < 0.001.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Cierny G., III 2011. Surgical treatment of osteomyelitis. Plast Reconstr Surg 127(Suppl 1):190S–204S. doi:10.1097/PRS.0b013e3182025070. - DOI - PubMed
    1. Chambers HF, Deleo FR. 2009. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol 7:629–641. doi:10.1038/nrmicro2200. - DOI - PMC - PubMed
    1. Lew DP, Waldvogel FA. 2004. Osteomyelitis. Lancet 364:369–379. doi:10.1016/S0140-6736(04)16727-5. - DOI - PubMed
    1. Rodvold KA, McConeghy KW. 2014. Methicillin-resistant Staphylococcus aureus therapy: past, present, and future. Clin Infect Dis 58(Suppl 1):S20–S27. doi:10.1093/cid/cit614. - DOI - PubMed
    1. Darley ES, MacGowan AP. 2004. Antibiotic treatment of gram-positive bone and joint infections. J Antimicrob Chemother 53:928–935. doi:10.1093/jac/dkh191. - DOI - PubMed

Publication types

MeSH terms